TG Therapeutics Email Formats
Biotechnology Research • 
3020 Carrington Mill Blvd, Suite 475, United States • 201-500 Employees
TG Therapeutics Email Formats
TG Therapeutics uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@tgtxinc.com), used 68.8% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@tgtxinc.com | 68.8% |
{first initial}.{last name} | j.doe@tgtxinc.com | 24.2% |
{first initial}{last name} | jdoe@tgtxinc.com | 4.6% |
Key Contacts at TG Therapeutics
Benn Richards
Director Regional Marketing
Kenneth Miller
Director
Jody Palmer
Director, Ms Key Accounts, Mid-Atlantic Region
Tori Stambaugh
Associate Director, Marketing
Karthik Bodhinathan
Director Medical Affairs
Joseph Cikowski
Director, Key Accounts
Jeffrey S. Wills
Associate Director Access And Reimbursement
Paula Campos
Director, Commercial Training And Execution
Michael Mcglynn
Associate Director Quality Assurance
Ian Houck
Senior Director, Access Marketing
Company overview
| Headquarters | 3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US |
| Phone number | +18775758489 |
| Websites | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Biotechnology, RMS, Multiple Sclerosis, B-Cell Diseases, Ublituximab, Subcutaneous, Azer-Cel |
| Founded | 2011 |
| Employees | 201-500 |
| Socials |
About TG Therapeutics
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline of investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) in Europe, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, Swissmedic in Switzerland, and Australia’s Therapeutic Goods Administration (TGA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
TG Therapeutics has 146 employees across 15 departments.
Departments
Number of employees
Funding Data
Explore TG Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
TG Therapeutics Tech Stack
Discover the technologies and tools that power TG Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
CDN
JavaScript graphics
JavaScript libraries
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Miscellaneous
Programming languages
Blogs
Analytics
Japan
Netherlands
Switzerland
Frequently asked questions
4.8
40,000 users
